Abstract
Based on the material available in both the scientific literature and on the web, the present paper provides an updated pharmacological, chemical, toxicological and behavioural overview of Bromo-Dragonfly (1-(8-bromobenzo[1,2- b;4,5-b]difuran-4-yl)-2-aminopropane; ‘ B-fly’). B-Fly is a powerful, long lasting, LSD-like, hallucinogenic drug, which has been associated with a number of acute intoxications and fatalities in a number of countries. A critical discussion of the potential of misuse of B-fly but also of the methodological limitations, which are intrinsically associated with the analysis of online, non-peer reviewed, material, is presented. It is concluded that the availability of online information on novel psychoactive drugs, such as B-fly, may constitute a public health challenge. Better international collaboration levels may be needed to tackle this novel and fast growing phenomenon
Keywords: ABDF, Bromo-Dragonfly, FLY-compounds, internet monitoring, phenethylamines, designer drugs, ReDNet project, research chemicals, psychoactive drugs
Current Clinical Pharmacology
Title: Designer Drugs on the Internet: A Phenomenon Out-of-Control? The Emergence of Hallucinogenic Drug Bromo-Dragonfly
Volume: 6 Issue: 2
Author(s): Liv Flesland, Norbert Scherbaum, Peer Van Der Kreeft, Cinzia Pezzolesi, Arvid Skutle, Holger Siemann, Harry Shapiro, Agnieszka Pisarska, Jacek Moskalewicz, Barbara Mervo, Ornella Corazza, Lucia Di Furia, Zsolt Demetrovics, Marta Torrens, Colin Drummond, Zoe Davey, Paolo Deluca, Magi Farre and Fabrizio Schifano
Affiliation:
Keywords: ABDF, Bromo-Dragonfly, FLY-compounds, internet monitoring, phenethylamines, designer drugs, ReDNet project, research chemicals, psychoactive drugs
Abstract: Based on the material available in both the scientific literature and on the web, the present paper provides an updated pharmacological, chemical, toxicological and behavioural overview of Bromo-Dragonfly (1-(8-bromobenzo[1,2- b;4,5-b]difuran-4-yl)-2-aminopropane; ‘ B-fly’). B-Fly is a powerful, long lasting, LSD-like, hallucinogenic drug, which has been associated with a number of acute intoxications and fatalities in a number of countries. A critical discussion of the potential of misuse of B-fly but also of the methodological limitations, which are intrinsically associated with the analysis of online, non-peer reviewed, material, is presented. It is concluded that the availability of online information on novel psychoactive drugs, such as B-fly, may constitute a public health challenge. Better international collaboration levels may be needed to tackle this novel and fast growing phenomenon
Export Options
About this article
Cite this article as:
Flesland Liv, Scherbaum Norbert, Van Der Kreeft Peer, Pezzolesi Cinzia, Skutle Arvid, Siemann Holger, Shapiro Harry, Pisarska Agnieszka, Moskalewicz Jacek, Mervo Barbara, Corazza Ornella, Di Furia Lucia, Demetrovics Zsolt, Torrens Marta, Drummond Colin, Davey Zoe, Deluca Paolo, Farre Magi and Schifano Fabrizio, Designer Drugs on the Internet: A Phenomenon Out-of-Control? The Emergence of Hallucinogenic Drug Bromo-Dragonfly, Current Clinical Pharmacology 2011; 6 (2) . https://dx.doi.org/10.2174/157488411796151129
DOI https://dx.doi.org/10.2174/157488411796151129 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Histone Modifications, Stem Cells and Prostate Cancer
Current Pharmaceutical Design Local Melatonin Regulates Inflammation Resolution: A Common Factor in Neurodegenerative, Psychiatric and Systemic Inflammatory Disorders
CNS & Neurological Disorders - Drug Targets Restless Leg Syndrome Associated with Atypical Antipsychotics: Current Status, Pathophysiology, and Clinical Implications
Current Drug Safety New Proposals for Treatment Sporadic Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry Pharmacological Treatment of ADHD and the Short and Long Term Effects on Sleep
Current Pharmaceutical Design Evaluation of Interactions Between Platinum-/Ruthenium-Based Anticancer Agents and Human Serum Albumin: Development of HSA Carrier for Metal-Based Drugs
Current Pharmaceutical Design Gonadal Hormones in Adolescent Females with β-Thalassemia in Relation to Iron Load
Endocrine, Metabolic & Immune Disorders - Drug Targets Cellular and Pharmacological Targets to Induce Coronary Arteriogenesis
Current Cardiology Reviews Selective Androgen Receptor Modulators Antagonize Apolipoprotein E4-Induced Cognitive Impairments
Letters in Drug Design & Discovery Interrelation Between Protein Synthesis, Proteostasis and Life Span
Current Genomics A Fluorene based Fluorogenic ''Turn-off'' Chemosensor for the Recognition of Cu<sup>2+</sup> and Fe<sup>2+</sup>: Computational Modeling and Living-cell Application
Current Analytical Chemistry Diagnosing and Treating Depression in Older and Oldest Old
Current Pharmaceutical Design 21-Hydroxy-6,19-epoxyprogesterone: A Promising Therapeutic Agent and a Molecular Tool for Deciphering Glucocorticoid Action
Mini-Reviews in Medicinal Chemistry Hypertension to Heart Failure: New Developmental Strategies do not Cross a Clinical and Therapeutic Divide
Current Pharmaceutical Design Treatment Considerations in the Forensic Patient with Schizophrenia
Current Pharmaceutical Design Ethnopharmacological and Phytopharmaceutical Evaluation of Prosopis cineraria: An Overview and Future Prospects
Current Drug Metabolism The Links between Cardiovascular Diseases and Alzheimer's Disease
Current Neuropharmacology The Cytokine Network in HIV Infection
Current Molecular Medicine Future Targets in Endometriosis Treatment: Targeting the Endometriotic Implant
Mini-Reviews in Medicinal Chemistry Modulation and Absorption of Xenobiotics: The Synergistic Role of CYP450 and P-gp Activities in Cancer and Neurodegenerative Disorders
Current Drug Metabolism